847033-99-2

Upstream product

• 847034-00-8 (R)-(-)-N-(propylidine)-p-toluenesulfinamide 
• 77385-90-1 N,N-dibenzylglycine ethyl ester 
• 247089-85-6 (R)-p-toluenesulfinamide 

Downstream Products

• 847034-01-9 (2S,3R)-(-)-3-[(R)-p-toluenesulfinylamino]-2-(dibenzylamino)-N-methoxy-N-methylpent-4-enamide 
• 847033-98-1 (-)-N-[(E,3R,4S)-4-(dibenzylamino)-5-oxoocta-1,6-dien-3-yl]-1H-pyrrole-2-carboxamide 
• 847034-02-0 (+)-N-[(1S,2R)-1-(N-methoxy-N-methylcarbamoyl)-1-(dibenzylamino)but-3-en-2-yl]-1H-pyrrole-2-carboxamide 
• 847034-05-3 N-benzyldebromoagelastatin A 
• 847034-03-1 (-)-pyrrole 
• 847033-97-0 (-)-N-[(1R,5S)-5-(dibenzylamino)-4-oxocyclopent-2-enyl]-1H-pyrrole-2-carboxamide 

Relevant academic research and scientific papers

ASYMMETRIC SYNTHESIS OF (-)-AGELASTATIN A

The total asymmetric synthesis of the cytotoxic marine metabolite (-)-agelastatin A (1) has been achieved from the C-ring intermediate 4,5-diamino cyclopenten-2-enone (-)-2. This key intermediate was efficiently prepared from the sulfinimine-derived α,β-d

Asymmetric total synthesis of (-)-agelastatin A using sulfinimine (N-sulfinyl imine) derived methodologies

(Chemical Equation Presented) The asymmetric synthesis of the cytotoxic marine metabolite (-)-agelastatin A (1) has been achieved from the C-ring intermediate 4,5-diamino cyclopenten-2-enone (-)-2. This key intermediate was efficiently prepared from the s